Who are Pabal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oxytocin 5 Usp Units In Dextrose 5%, Oxytocin 2 mIU/mL, syntocinon nasal spray, oxytocin nasal spray, Oxytocin + misoprostol, Oxytocin bolus or oxytocin infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carbetocin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pabal — Competitive Intelligence Brief

Pabal (CARBETOCIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: carbetocin. Area: Other.

marketed carbetocin Oxytocin receptor Other Recombinant protein Live · refreshed every 30 min

Target snapshot

Pabal (CARBETOCIN) — Ferring Pharmaceuticals Ltd.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pabal TARGET	CARBETOCIN	Ferring Pharmaceuticals Ltd	marketed	carbetocin	Oxytocin receptor
Oxytocin 5 Usp Units In Dextrose 5%	OXYTOCIN	Fresenius Kabi	marketed	Adrenocorticotropic Hormone [EPC]	Oxytocin receptor	1980-01-01
Oxytocin 2 mIU/mL	Oxytocin 2 mIU/mL	Assistance Publique - Hôpitaux de Paris	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)
syntocinon nasal spray	syntocinon nasal spray	Rambam Health Care Campus	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)
oxytocin nasal spray	oxytocin nasal spray	University of Electronic Science and Technology of China	marketed	Neuropeptide	Oxytocin receptor (OXTR)
Oxytocin + misoprostol	Oxytocin + misoprostol	Ain Shams Maternity Hospital	marketed	Uterotonic agents	Oxytocin receptor; prostaglandin E1 receptor (EP receptor)
Oxytocin bolus or oxytocin infusion	Oxytocin bolus or oxytocin infusion	Stony Brook University	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (carbetocin class)

Ferring Pharmaceuticals Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pabal — Competitive Intelligence Brief. https://druglandscape.com/ci/carbetocin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab